Colin Sambrook Smith

Colin joined Sygnature in May 2012 to take on a newly-created role to manage computational science and informatics at Sygnature.

He is an experienced computational chemist and research manager with a proven ability to analyse and determine the scientific computing and information technology needs of research-based organisations. Colin has 27 years of R&D experience within the pharmaceutical industry. He started his career at Akzo Nobel and then moved to OSI Pharmaceuticals, before transferring to OSI Prosidion. His most recent role at Prosidion (Oxford, UK) was Director of Research Technologies where he was responsible for informatics, computational chemistry, array chemistry and analytical chemistry. He was also a member of the Research Steering Group which set and reviewed all research priorities and goals for Prosidion.

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…